By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.